All In Biotech

Drug Trial Radar · NCT06229145

A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

A Phase 4, Randomized, Double-blind, Multicenter Non-inferiority Trial Evaluating the Efficacy and Safety of Intravenous KRYSTEXXA® (Pegloticase) Administered Every 4 Weeks Compared With KRYSTEXXA Administered Every 2 Weeks With Co-administration of Weekly Doses of Methotrexate, Followed by an Open-label Extension, in Participants With Uncontrolled Refractory Gout (FORWARD II)

Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 306 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

306

Actual

Start

Mar 18, 2024

Primary completion

Jul 30, 2025

Study completion Mar 26, 2026

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Jan 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study consists of 24-week double-blind trial to evaluate the non-inferiority of the efficacy and safety of pegloticase Q4W with MTX versus pegloticase Q2W with MTX, followed by a 24-week open-label extension of pegloticase Q4W with MTX, in participants with uncontrolled refractory gout. The main objective of the study is to evaluate the effect of pegloticase 16 mg administered Q4W with MTX versus pegloticase 8 mg administered Q2W with MTX, on the response rate during Month 6, as measured by the sustained normalization of sUA to \< 6 mg/dL for at least 80% of the time.

Conditions

  • Gout

Interventions

  • PegloticaseBiological

    IV infusion

  • MethotrexateDrug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6Time frame: Month 6 (Weeks 20, 21, 22, 23, and 24)

Locations

74 sites in 1 country. Site status is shown where the registry gives one.

  • The University of Alabama at Birmingham (UAB)

    Birmingham, Alabama

  • Orthopedic Physicians Alaska - Rheumatology and Infusion

    Anchorage, Alaska

  • Arizona Arthritis and Rheumatology Associates - Chandler

    Chandler, Arizona

  • Arizona Arthritis and Rheumatology Rese

    Flagstaff, Arizona

  • Arizona Arthritis & Rheumatology Research, PLLC

    Gilbert, Arizona

  • Arizona Arthritis & Rheumatology Research, PLLC

    Mesa, Arizona

  • Arizona Arthritis and Rheumatology Research, PLLC

    Mesa, Arizona

  • Arizona Arthritis and Rheumatology Research, PLLC

    Phoenix, Arizona

  • Arizona Arthritis and Rheumatology Research

    Phoenix, Arizona

  • Arizona Arthritis & Rheumatology Research, PLLC

    Sun City, Arizona

  • Arizona Arthritis and Rheumatology

    Tucson, Arizona

  • Covina Arthritis Clinic

    Covina, California

  • Medvin Clinical Research- Riverside

    Hemet, California

  • Velocity Clinical Research - Boise - ERN - PPDS

    North Hollywood, California

  • TriWest Research Associates

    San Diego, California

  • Precision Comprehensive Clinical Research Solutions

    San Leandro, California

  • Saint John's Health Center - Providence St John's Health Ctr

    Santa Monica, California

  • C.V. Mehta MD Medical Corporation

    Temecula, California

  • Foothill Arthritis

    Tujunga, California

  • Medvin Clinical Research

    Whittier, California

  • University of Colorado Denver

    Aurora, Colorado

  • Lynn Institute of the Rockies

    Colorado Springs, Colorado

  • Denver Arthritis Clinic - Rheumatology

    Denver, Colorado

  • Arthritis & Rheumatic Disease

    Aventura, Florida

  • Prohealth Research Center

    Doral, Florida

  • Life Clinical Trials

    Margate, Florida

  • Homestead Associates in Research,Inc

    Miami, Florida

  • D&H National Research Centers, Inc.

    Miami, Florida

  • Well Pharma

    Miami, Florida

  • Felicidad Medical Research, LLC.

    Miami, Florida

  • New Generation Of Medical Research

    Naples, Florida

  • IRIS Research & Development

    Plantation, Florida

  • D&H Pompano Research Center

    Pompano Beach, Florida

  • D&H Tamarac Research Center

    Tamarac, Florida

  • GCP Clinical Research

    Tampa, Florida

  • ClinPro Research Solutions, LLC

    Tampa, Florida

  • Arthritis Center of North Georgia

    Gainesville, Georgia

  • Vista Clinical Research, LLC

    Newnan, Georgia

  • Great Lakes Clin. Trials

    Chicago, Illinois

  • Conquest Research - Anesthesiology/Pain Medicine

    Chicago, Illinois

Showing 40 of 74 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.